title: Intracellular polymerization. Disease severity and therapeutic predictions.
abstract: The extent of intracellular polymerization of hemoglobin S, leading to loss of erythrocyte deformability and eventual morphological sickling, is primarily determined by oxygen saturation and intracellular hemoglobin concentration and composition. Epidemiological analysis of sickle cell disease severity among the sickle syndromes and studies of the biophysics of intracellular polymerization were used to estimate the potential clinical benefit of various therapeutic strategies. These strategies include those designed to increase deoxyhemoglobin S solubility; to increase erythrocyte volume or water content, thereby reducing the intracellular hemoglobin concentration; or, most recently, to decrease the proportion of hemoglobin S by increasing the amount of non-S hemoglobin. Increasing levels of hemoglobin F is of particular interest due to its "sparing" effect in inhibiting polymerization, the well-characterized epidemiological associations of high levels of hemoglobin F with reduced disease severity, and recent studies of drug-induced increases in hemoglobin F. Our analyses of equilibrium polymer formation at physiological oxygen saturation values suggest that small decreases in polymer formation at intermediate levels of hemoglobin F may give rise to a small decrease in anemia (as associated with homozygous alpha-thalassemia coexistent with sickle cell anemia), but that greater reductions in polymer formation may be necessary to effect a significant improvement in disease severity. Current studies of hydroxyurea-induced increases of hemoglobin F give cautious optimism that therapeutically useful levels may be attainable.
authors: Laboratory of Chemical Biology, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892.
authors: C T
authors: CT
authors: Noguchi
authors: G P
authors: GP
authors: Rodgers
authors: A N
authors: AN
authors: Schechter
mesh_terms: D000755:Anemia, Sickle Cell / Q000235:genetics / Q000378:metabolism* / Q000628:therapy; D004907:Erythrocyte Deformability; D005319:Fetal Hemoglobin / Q000032:analysis / Q000235:genetics; D006451:Hemoglobin, Sickle / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D009682:Magnetic Resonance Spectroscopy; D010100:Oxygen / Q000097:blood; D011108:Polymers; D013816:Thermodynamics
chemical_list: D006451:Hemoglobin, Sickle; D011108:Polymers; C038875:deoxyhemoglobin, sickle; D005319:Fetal Hemoglobin; D010100:Oxygen